We partner with founders confronting hard biology — capital that stays the course through long clinical timelines.
Building a medicine is among the most demanding undertakings in modern enterprise. The science is unforgiving, the timelines are measured in decade-fractions, and the path from hypothesis to patient runs through regulatory and clinical thresholds that fund capital is rarely structured to weather. KMFE invests in this terrain because we believe the most consequential companies of the coming decades will be those that translate biological complexity into outcomes patients can feel.
The patient is the test that matters.
We back foundational technologies.
Compute, materials, and the systems that quietly reshape how the world works. Long horizons, deep conviction.
The technologies that matter most are rarely the ones that announce themselves. They sit beneath the layer the world sees — the silicon, the materials science, the engineered systems that make the next decade of progress possible. Backing this kind of work demands a willingness to wait, to fund through the years before commercial validation arrives, and to engage with the technical detail rather than the narrative around it.
We measure progress in decades, not quarters.
Sovereign capabilities matter.
We invest in dual-use technologies and the industrial base that secures free societies for the next generation.
The defence of free societies has become inseparable from the technologies that underwrite their economic and informational sovereignty. Compute, autonomy, sensing, materials, advanced manufacturing — these are no longer adjacent to defence; they are its substance. KMFE invests where commercial advantage and strategic resilience converge, in companies building dual-use capabilities that serve both private markets and the institutions on which open societies depend.
Resilience is the most undervalued asset of our time.